Status:

UNKNOWN

Glumetinib Combined With Toripalimab in the Treatment of Relapsed or Metastatic Non-small Cell Lung Cancer.

Lead Sponsor:

Shanghai Junshi Bioscience Co., Ltd.

Conditions:

Relapsed or Metastatic Non-small Cell Lung Cancer

Eligibility:

All Genders

18-75 years

Phase:

PHASE1

PHASE2

Brief Summary

This is an open-label, multicenter Phase Ib/II registration clinical study, consisting of two parts: the Phase Ib dose-climbing study and the Phase II efficacy exploration study. Phase Ib : Phase Ib...

Eligibility Criteria

Inclusion

  • Inclusion criteria:
  • Subsubjects with histologically or cytologically confirmed NSCLC, clinically diagnosed as locally advanced (stage IIIB or IIIC) and stage IV NSCLC (according to AJCC 8th edition staging), EGFR wild-type, negative for ALK and ROS1 rearrangement, and no Met exon14 skipping mutation; genetic testing is not mandatory for subjects with squamous cell cancer;
  • PD - L1 expression of 1% or higher.
  • Non-small cell lung cancer patients following failure of or were intolerance to previous standard treatment (chemotherapy and immunotherapy alone or in combination) and received no more than third-line treatment;
  • At least 1 measurable tumor lesion according to RECIST1.1 criteria.
  • Subjects must provide valid and qualified tissue samples (fresh biopsy or preserved tumor tissue samples are acceptable, but fresh biopsy samples are preferred).
  • ECOG score ≤1 point;
  • Sufficient function of bone marrow, liver and kidney organs.
  • Exclusion criteria:
  • Pathological diagnosis confirmed the presence of small cell lung cancer;
  • The patient was currently participating in and receiving other studies or had previously received another c-Met inhibitor;
  • There are mutations/rearrangements of EGFR, ALK, ROS1, Met14 exon skipping;

Exclusion

    Key Trial Info

    Start Date :

    April 15 2021

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    February 26 2024

    Estimated Enrollment :

    67 Patients enrolled

    Trial Details

    Trial ID

    NCT04797702

    Start Date

    April 15 2021

    End Date

    February 26 2024

    Last Update

    March 15 2021

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Guangdong Provincial People's Hospital

    Guangzhou, Guangdong, China, 510180